Jagsonpal Pharmaceuticals has informed that the Board of Directors at their meeting held today has approved changes in KMPs authorized for the purpose of determining materiality of an event or information and for the purpose of making disclosures to stock exchange(s) under the SEBI LODR. The contact details of the KMPs authorized is enclosed.
The above information is a part of company’s filings submitted to BSE.